Terms of use

Terms of Use

The logos of various companies displayed on Fey.com are for editorial and informational purposes only. Fey.com is not affiliated with, sponsored by, or endorsed by these companies. All logos are trademarks of their respective owners and are used under the principles of fair use. We make no claim of ownership over these trademarks.

Restrictions on Use

While we provide these logos for individual download and personal use, any form of automated scraping or bulk downloading of logos from Fey.com is strictly prohibited. Users are permitted to download logos manually, one at a time, as intended through our user interface. Unauthorized mass retrieval or use of logos will be considered a violation of our terms and may result in restricted access or legal action. For concerns or inquiries regarding the use of any logo, please contact us at info@fey.com.

ALZN Alzamend Neuro Inc.
Alzamend Neuro logo

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.